Campbell & Co Investment Adviser’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $309K | Buy |
+8,486
| New | +$309K | 0.02% | 944 |
|
|
2025
Q1 | – | Sell |
-39,694
| Closed | -$1.67M | – | 1284 |
|
|
2024
Q4 | $1.67M | Buy |
+39,694
| New | +$1.67M | 0.13% | 226 |
|
|
2024
Q3 | – | Sell |
-33,868
| Closed | -$1.39M | – | 1287 |
|
|
2024
Q2 | $1.39M | Buy |
+33,868
| New | +$1.39M | 0.12% | 255 |
|
|
2022
Q4 | – | Sell |
-10,086
| Closed | -$418K | – | 954 |
|
|
2022
Q3 | $418K | Buy |
+10,086
| New | +$418K | 0.1% | 369 |
|
|
2022
Q2 | – | Sell |
-7,580
| Closed | -$550K | – | 872 |
|
|
2022
Q1 | $550K | Buy |
7,580
+3,680
| +94% | +$267K | 0.15% | 239 |
|
|
2021
Q4 | $328K | Buy |
3,900
+650
| +20% | +$54.7K | 0.11% | 331 |
|
|
2021
Q3 | $293K | Buy |
3,250
+700
| +27% | +$63.1K | 0.1% | 378 |
|
|
2021
Q2 | $243K | Sell |
2,550
-1,050
| -29% | -$100K | 0.1% | 387 |
|
|
2021
Q1 | $410K | Buy |
+3,600
| New | +$410K | 0.25% | 138 |
|
|
2019
Q4 | – | Sell |
-13,244
| Closed | -$567K | – | 818 |
|
|
2019
Q3 | $567K | Buy |
+13,244
| New | +$567K | 0.21% | 147 |
|
|
2019
Q1 | – | Sell |
-8,790
| Closed | -$423K | – | 594 |
|
|
2018
Q4 | $423K | Buy |
+8,790
| New | +$423K | 0.42% | 61 |
|